{"id":"NCT00165672","sponsor":"Eisai Inc.","briefTitle":"A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease","officialTitle":"A Clinical Pharmacology Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2005-10","completion":"2005-10","firstPosted":"2005-09-14","resultsPosted":"2011-10-05","lastUpdate":"2011-10-05"},"enrollment":26,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Non-erosive Gastroesophageal Reflux Disease"],"interventions":[{"type":"DRUG","name":"RABEPRAZOLE SODIUM","otherNames":[]},{"type":"DRUG","name":"RABEPRAZOLE SODIUM","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)).","primaryOutcome":{"measure":"The Percent Time With pH <4.0 During 24 Hour Esophageal pH Monitoring at the End of the Observation Period (Predose Monitoring) and at the End of the Treatment Period (Postdose Monitoring).","timeFrame":"Baseline and 4 weeks","effectByArm":[{"arm":"E3810 Pariet (Rabeprazole Sodium) 5 mg","deltaMin":6.72,"sd":5.3},{"arm":"E3810 Pariet (Rabeprazole Sodium) 10 mg","deltaMin":7.03,"sd":4.76}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":13,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["Diarrhoea","Headache","Cough","Abdominal distension","Gastrooesophageal reflux disease"]}}